Another AZ exec jumps ship for CEO job at smaller drugmaker

AstraZeneca ($AZN) has lost its second top executive in less than two weeks, as VP James Ward-Lilley bids goodbye to Big Pharma to run the respiratory specialist Vectura--which happens to have partnerships with AZ lung-drug rivals GlaxoSmithKline ($GSK) and Novartis ($NVS). Currently head of AZ's portfolio strategy in respiratory, inflammation and autoimmunity, Ward-Lilley will join Vectura Oct. 1. Story | Release

Suggested Articles

FDA researchers uncover more concerns and fears among front-line workers and minority groups about a COVID-19 vaccine.

Provention Bio wants to connect the familial threads around Type 1 diabetes with two new campaigns—one targeted at doctors and the other at consumers.

Novartis’ latest campaign with a celebrity dance partner asks people to bust a move to raise awareness around sickle cell anemia and therapy Adakveo.